Chen Jianqi, Cao Xu, Xu Shengsong, Chen Xuhao, Xie Rui, Ye Guitong, Zhang Yuan, Huang Shaofen, Shen Xinyue, Xiao Yue, Zhan Jinan, Zhu Yingting, Zhuo Yehong
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yatsen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, 510060, Guangdong Province, China.
EClinicalMedicine. 2024 Sep 25;76:102860. doi: 10.1016/j.eclinm.2024.102860. eCollection 2024 Oct.
Retinoblastoma is considered a lethal but curable malignancy often presenting in childhood. We investigated its global, regional, and national burden among infants and young children from 1990 to 2021.
We obtained data on retinoblastoma incidence, prevalence, mortality, and disability-adjusted life years (DALYs) from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021. Trends were analysed using joinpoint regression to calculate annual percentage changes. Spearman's rank correlation and locally estimated scatterplot smoothing regression were used to assess the relationship between retinoblastoma burden and sociodemographic index.
In 2021, the global incidence, prevalence, mortality, and DALYs of retinoblastoma were 0.82 (95% uncertainty interval [UI], 0.48-1.10), 7.46 (95% UI, 4.42-10.08), 0.37 (95% UI, 0.22-0.51), and 32.81 (95% UI, 19.9-45.21), respectively. From 1990 to 2021, the global incidence and prevalence rates of retinoblastoma increased, with average annual percentage changes (AAPCs) of 0.67 (95% confidence interval [CI], 0.49-0.85] and 0.68 (95% CI, 0.50-0.86), respectively. Conversely, those of related mortality and DALYs decreased, with AAPCs of -0.64 (95% CI, -0.79 to -0.49) and -0.63 (95% CI, -0.78 to -0.48), respectively. Children aged 2-4 years and those in low-income regions exhibited the highest burden. Negative correlations were found between sociodemographic index and retinoblastoma burden.
Advancements in retinoblastoma detection and treatment have increased its reported incidence and prevalence while reducing its mortality and DALYs. Nonetheless, substantial socioeconomic and geographic disparities persist. In low-income countries, the incidence has decreased, possibly reflecting challenges such as limited healthcare access and underreporting, necessitating targeted interventions and improved healthcare access.
National Key R&D Project of China (2020YFA0112701), Natural Science Foundation of Guangdong Province (2024A1515013058), and Science and Technology Program of Guangzhou, China (202206080005).
视网膜母细胞瘤被认为是一种致命但可治愈的恶性肿瘤，常见于儿童期。我们调查了1990年至2021年全球、区域和国家层面婴幼儿视网膜母细胞瘤的负担情况。
我们从《2021年全球疾病、伤害及风险因素负担研究》中获取了视网膜母细胞瘤发病率、患病率、死亡率和伤残调整生命年（DALY）的数据。采用Joinpoint回归分析趋势，计算年度百分比变化。使用Spearman等级相关和局部加权散点平滑回归评估视网膜母细胞瘤负担与社会人口学指数之间的关系。
2021年，全球视网膜母细胞瘤的发病率、患病率、死亡率和伤残调整生命年分别为0.82（95%不确定区间[UI]，0.48 - 1.10）、7.46（95% UI，4.42 - 10.08）、0.37（95% UI，0.22 - 0.51）和32.81（95% UI，19.9 - 45.21）。1990年至2021年，全球视网膜母细胞瘤的发病率和患病率上升，平均年度百分比变化（AAPC）分别为0.67（95%置信区间[CI]，0.49 - 0.85）和0.68（95% CI，0.50 - 0.86）。相反，相关的死亡率和伤残调整生命年下降，AAPC分别为 - 0.64（95% CI， - 0.79至 - 0.49）和 - 0.63（95% CI， - 0.78至 - 0.48）。2至4岁儿童和低收入地区儿童的负担最高。社会人口学指数与视网膜母细胞瘤负担之间存在负相关。
视网膜母细胞瘤检测和治疗方面的进展提高了报告的发病率和患病率，同时降低了死亡率和伤残调整生命年。尽管如此，社会经济和地理差异仍然很大。在低收入国家，发病率有所下降，这可能反映了诸如医疗服务可及性有限和报告不足等挑战，因此需要有针对性的干预措施并改善医疗服务可及性。
国家重点研发计划项目（2020YFA0112701）、广东省自然科学基金（2024A1515013058）以及中国广州市科技计划项目（202206080005）
